PAA 2.50% 20.5¢ pharmaust limited

Ann: Phase IIb Dog Trial Achieves Interim Clinical Endpoints, page-122

  1. 2,408 Posts.
    lightbulb Created with Sketch. 1494
    Kpax,

    when you can spare a moment, could you comment on Elanco's current VDC 597 mTOR project and any similar current projects that you may be aware of and how they compare to PAAs mpl project. I recall you mentioning them in the past and saying "we're way ahead". No rush but it'd be much appreciated.

    https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0200634



    Last edited by Lastly: 22/07/21
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.